NOVEL ORAL ANTICOAGULANTS ARE SAFE AND EFFECTIVE FOR THROMBOEMBOLIC PROPHYLAXIS IN OBESE PATIENTS WITH ATRIAL FIBRILLATION

The prevalence of obesity in U.S. adults is 38% and class III obesity (BMI ≥40 kg/m2) approaches 8%, many have comorbid atrial fibrillation (AF). Recent recommendations caution against novel oral anticoagulant (NOAC) use for thromboembolic (TE) prophylaxis in obese patients and advise against use